Cartilage defect disease Global No.1 ATEMs
Cartilage defect disease Global No.1 ATEMs
With the research experience of applying cell therapy to
clinical trials for the first time in Korea,
We are continuously researching and developing cell
therapy products and tissue engineering therapies.
ATEMs Co., Ltd. strives to develop innovative regenerative medicine
products and treat incurable diseases through collaboration with
domestic and foreign clinical research teams (Aju University Hospital,
Cha Medical Center, Asan Medical Center, Seoul National University Hospital,
Shanghai Transportation University Hospital, and University Malaya Medical
Center, etc.) and specialty groups in the regenerative medicine area
(Pukyong National University, Inha University, Institute of Machinery and Materials,
Atomic Energy Research Institute, Asan Institute for Life Sciences, Singapore
A*STAR, and Yanbian University).
With the research experience of applying cell therapy to
clinical trials for the first time in Korea,
We are continuously researching and developing cell
therapy products and tissue engineering therapies.
ATEMs Co., Ltd. strives to develop innovative regenerative medicine
products and treat incurable diseases through collaboration with domestic
and foreign clinical research teams (Aju University Hospital, Cha Medical
Center, Asan Medical Center, Seoul National University Hospital, Shanghai
Transportation University Hospital, and University Malaya Medical Center,
etc.) and specialty groups in the regenerative medicine area (Pukyong
National University, Inha University, Institute of Machinery and Materials,
Atomic Energy Research Institute, Asan Institute for Life Sciences,
Singapore A*STAR, and Yanbian University).